(Q37013035)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18035960%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

review article

1 reference

title

Latest treatment strategies for membranous nephropathy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18035960%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18035960%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

Giuseppe Remuzzi

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18035960%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1

Piero Ruggenenti

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18035960%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

language of work or name

English

0 references

publication date

1 December 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18035960%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Pharmacotherapy

27 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18035960%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18035960%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

issue

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18035960%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

page(s)

3159-3171

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18035960%20AND%20SRC:MED&resulttype=core&format=json

Molecular pathomechanisms of membranous nephropathy: from Heymann nephritis to alloimmunization

27 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3159

Cellular response to injury in membranous nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3159

Management of membranous nephropathy: when and what for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3159

A review of therapeutic studies of idiopathic membranous glomerulopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3159

Mycophenolate mofetil treatment for primary glomerular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3159

Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3159

Prognostic factors in idiopathic membranous nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3159

Urinary excretion of IgG and alpha(1)-microglobulin predicts clinical course better than extent of proteinuria in membranous nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3159

Idiopathic membranous nephropathy: outline and rationale of a treatment strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3159

Experimental membranous nephropathy redux

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3159

Immunocytochemical localization of the Heymann nephritis antigen (GP330) in glomerular epithelial cells of normal Lewis rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3159

Contrasting roles of complement activation and its regulation in membranous nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3159

Increased urinary excretion of C5b-9 distinguishes passive Heymann nephritis in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3159

Urinary excretion of complement C3d in patients with renal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3159

A nephritogenic rat monoclonal antibody to mouse aminopeptidase A. Induction of massive albuminuria after a single intravenous injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3159

Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3159

Drug insight: rituximab in renal disease and transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3159

Rituximab in idiopathic membranous nephropathy: a one-year prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3159

Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3159

Nature of the glomerular capillary injury in human membranous glomerulopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3159

Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3159

Use of mycophenolate mofetil in resistant membranous nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3159

A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3159

Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3159

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3159

How to fully protect the kidney in a severe model of progressive nephropathy: a multidrug approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3159

Permselective dysfunction of podocyte-podocyte contact upon angiotensin II unravels the molecular target for renoprotective intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3159

ACE inhibition improves glomerular size selectivity in patients with idiopathic membranous nephropathy and persistent nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3159

Retarding progression of chronic renal disease: the neglected issue of residual proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3159

Progression, remission, regression of chronic renal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3159

Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3159

Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3159

Statins in nephrotic syndrome: a new weapon against tissue injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3159

Controlled trial of cyclophosphamide in idiopathic membranous nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3159

A Randomized, Controlled Trial of Steroids and Cyclophosphamide in Adults with Nephrotic Syndrome Caused by Idiopathic Membranous Nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3159

Prognosis of Untreated Patients with Idiopathic Membranous Nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3159

Rituximab for idiopathic membranous nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3159

Rituximab for Idiopathic Membranous Nephropathy: Who Can Benefit?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3159

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3159

Overview of randomised trials of ACE inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3159

Nonimmunosuppressive therapy of membranous nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3159

Depletion of clusterin in renal diseases causing nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3159

Immunosuppressive treatment for idiopathic membranous nephropathy: A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.18.3159

10.1517/14656566.8.18.3159

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18035960%20AND%20SRC:MED&resulttype=core&format=json

27 December 2019

1 reference